They’re rolling up their sleeves again, seemingly out of fear of missing AI’s defining moment and, presumably, the irresistible allure of making even more money — potentially a lot more.
Related Posts
Bristol Myers Squibb buys Nvidia AI system for drug discovery
Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker’s Vera Rubin architecture to support…
ChatGPT finally offers $100/month Pro plan
OpenAI announced on Thursday something that power users have been asking for: a $100/month plan. Previously, subscriptions jumped…
NEA’s Tiffany Luck on AI IPOs, personal agents, and the ROI reckoning
Tokenmaxxing was the hottest trend in Silicon Valley earlier this year, with CEOs encouraging employees to push AI usage as…